Get the Stockscreener App
62.10
2.18%
-1.19
Bright Minds Biosciences Inc stock is traded at $62.10, with a volume of 5,630.
It is down -2.18% in the last 24 hours and up +26.99% over the past month.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$63.29
Open:
$63.64
24h Volume:
5,630
Relative Volume:
0.08
Market Cap:
$444.12M
Revenue:
-
Net Income/Loss:
$-4.98M
P/E Ratio:
-47.13
EPS:
-1.3177
Net Cash Flow:
$-3.85M
1W Performance:
+20.21%
1M Performance:
+26.99%
6M Performance:
+114.74%
1Y Performance:
+5,633%
1-Day Range:
$61.37
$65.00
1-Week Range:
$48.94
$65.00
52-Week Range:
$1.11
$79.02
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
63.05 | 448.64M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.19 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.29 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.50 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.59 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | BTIG Research | Buy |
| May-13-25 | Initiated | TD Cowen | Buy |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
View All
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Has Bright Minds Biosciences Inc. found a price floorJuly 2025 WrapUp & Entry Point Strategy Guides - newser.com
Insiders Who Sold CA$17m Of Bright Minds Biosciences Made The Right Call - simplywall.st
Published on: 2025-10-10 09:53:23 - newser.com
Exit strategy if you’re trapped in Bright Minds Biosciences Inc.2025 AllTime Highs & Intraday High Probability Alerts - newser.com
Risk vs reward if holding onto Bright Minds Biosciences Inc.Analyst Downgrade & Free Long-Term Investment Growth Plans - newser.com
How to use Fibonacci retracement on Bright Minds Biosciences Inc.July 2025 WrapUp & AI Enhanced Trading Alerts - newser.com
What technical models suggest about Bright Minds Biosciences Inc.’s comebackQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com
Regression analysis insights on Bright Minds Biosciences Inc. performanceMarket Performance Summary & AI Powered Market Entry Ideas - newser.com
Published on: 2025-10-09 04:28:20 - newser.com
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives $81.00 Consensus Target Price from Analysts - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Stock Rating Lowered by Wall Street Zen - Defense World
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Rating of "Buy" from Analysts - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Cut to Sell at Wall Street Zen - MarketBeat
Will Bright Minds Biosciences Inc. stock outperform growth indexesJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
BTIG Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Maintains Target Price $72 - 富途牛牛
Published on: 2025-09-30 11:54:24 - earlytimes.in
What analysts say about Bright Minds Biosciences Inc stockResistance Zone Identification & High Return Investment Plans - earlytimes.in
Is Bright Minds Biosciences Inc a good long term investmentMarket Liquidity Analysis & Explosive Capital Growth Plans - earlytimes.in
What drives Bright Minds Biosciences Inc stock priceAI-Driven Market Analysis & Low Risk Investment Growth - earlytimes.in
Bright Minds Biosciences Inc Stock Analysis and ForecastCandlestick Pattern Analysis & Fast Profit Stock Ideas - Early Times
H.C. Wainwright Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Maintains Target Price $85 - 富途牛牛
Goldman Sachs Group Inc. Takes Position in Bright Minds Biosciences Inc. $DRUG - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Rating Increased to Hold at Wall Street Zen - MarketBeat
Relative strength of Bright Minds Biosciences Inc. in sector analysisProduct Launch & Stepwise Entry/Exit Trade Alerts - newser.com
Using data filters to optimize entry into Bright Minds Biosciences Inc.July 2025 Gainers & Precise Buy Zone Identification - newser.com
Bright Minds Biosciences (NASDAQ:DRUG) Upgraded by Wall Street Zen to Hold Rating - Defense World
Chart based analysis of Bright Minds Biosciences Inc. trendsEarnings Trend Report & High Accuracy Trade Alerts - newser.com
Portfolio Update: How is Bright Minds Biosciences Inc managing supply chain issues2025 Winners & Losers & Free High Return Stock Watch Alerts - khodrobank.com
How to forecast Bright Minds Biosciences Inc. trends using time seriesOptions Play & Fast Gain Stock Trading Tips - newser.com
What data driven models say about Bright Minds Biosciences Inc.’s futureMarket Performance Report & Verified Short-Term Trading Plans - newser.com
HC Wainwright Reaffirms "Buy" Rating for Bright Minds Biosciences (NASDAQ:DRUG) - MarketBeat
Aug Sectors: What is HIPOs 5 year growth outlookEarnings Performance Report & Technical Pattern Based Signals - khodrobank.com
S P Trends: What is Bright Minds Biosciences Inc. s revenue forecast2025 Biggest Moves & Precise Buy Zone Tips - خودرو بانک
Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade - Yahoo Finance
Bright Minds Biosciences Reports Q3 2025 Financial Results - MSN
Growth Report: Is Driven Brands Holdings Inc. undervalued by DCF analysisJuly 2025 Weekly Recap & High Conviction Trade Alerts - خودرو بانک
Bright Minds rebounds after $35M private placement - MSN
Will Bright Minds Biosciences Inc benefit from rate cutsJuly 2025 Final Week & Short-Term High Return Strategies - خودرو بانک
Surprises Report: What is Bright Minds Biosciences Incs valuation compared to sectorPortfolio Value Report & Real-Time Price Movement Reports - خودرو بانک
Gap Down: Can GTES sustain earnings growth2025 Top Gainers & Stock Portfolio Risk Control - khodrobank.com
Insider Buy: Will Bright Minds Biosciences Inc benefit from AI trends2025 Stock Rankings & Entry Point Confirmation Alerts - خودرو بانک
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bright Minds Biosciences Inc Stock (DRUG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 10% Owner |
Oct 15 '24 |
Buy |
5.53 |
372,591 |
2,061,574 |
825,000 |
| Cormorant Asset Management, LP | 10% Owner |
Oct 16 '24 |
Buy |
23.46 |
50,000 |
1,172,813 |
875,000 |
2.36%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):